AbbVie (ABBV)
Large pharmaceutical company spun off from Abbott in 2013, with immunology blockbusters Skyrizi and Rinvoq succeeding Humira, plus the Allergan aesthetics portfolio (Botox).
- Legal name
- AbbVie Inc.
- Ticker
- ABBV
- Exchange
- New York Stock Exchange · MIC XNYS
- Country
- United States
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Market cap ≈
- $451.5bn — computed, not copied: 1.767bn shares × $255.48 close on 2026-08-28
- Reporting currency
- USD
- Founded
- 2013
- Website
- www.abbvie.com
- LEI
- FR5LCKFTG8054YNNRU85 (GLEIF)
- ISIN
- US00287Y1091 (check digit validated)
- FIGI
- BBG0025Y4RZ3 (share class, OpenFIGI)
Graph connections view in graph →
lists_onNew York Stock Exchange
domiciled_inUnited States
member_ofS&P 500
Sector peers — Healthcare
Eli Lilly · UnitedHealth Group · Johnson & Johnson · Merck & Co. · Thermo Fisher Scientific · Abbott
Compare: ABBV vs LLY · ABBV vs UNH · ABBV vs JNJ
How this market cap is arrived at
| Shares outstanding | 1,767,117,285 |
| Basis | outstanding |
| As of | 2026-06-30 |
| Source | SEC 10-Q cover page (2026-06-30) |
| Price | 255.48 USD · ABBV · close 2026-08-28 |
| Venue | NYSE |
| Market cap | $451.5bn |
US-domiciled, no ADR. Single class. Very stable count — it has moved less than 0.1% over the past year (1,766.6m at 2025-07-29 to 1,767.1m at 2026-07-27) as buybacks roughly offset compensation issuance, so staleness risk is minimal here.
Share counts move on a filing cadence, prices move continuously — so this figure is exact only as of the two dates above, and we publish both rather than a single undated number. Provenance.
Fundamentals
| From the 10-K for the year ended 2025-12-31 | USD | As reported |
|---|---|---|
| Revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $61.2bn | |
| Operating incomeus-gaap:OperatingIncomeLoss | $15.1bn | |
| Net incomeus-gaap:NetIncomeLoss | $4.2bn | |
| Total assetsus-gaap:Assets | $134.0bn | |
| Shareholders' equityus-gaap:StockholdersEquity | $-3.3bn | |
| Cash & equivalentsus-gaap:CashAndCashEquivalentsAtCarryingValue | $5.2bn |
Net margin 6.9% — net income divided by revenue, both from this same filing.
Market cap / net income 106.8× — a market value from 2026-08-28 divided by earnings for a year that ended 2025-12-31. The two dates are far apart on purpose: this is arithmetic on two published numbers, not a valuation.
Every figure above is read from the same 10-K, filed 2026-02-20, and each row names the XBRL tag it came from so it can be checked against the document. Metrics absent from that filing are absent here rather than sourced from a different year — a table mixing periods is individually true and collectively meaningless.
Identifier crosswalk
| Standard | Value | What it answers |
|---|---|---|
| Ticker | ABBV | Venue-local shorthand — ambiguous across markets |
| MIC | XNYS | ISO 10383 — the venue |
| ISIN | US00287Y1091 | ISO 6166 — the security |
| LEI | FR5LCKFTG8054YNNRU85 | ISO 17442 — the legal entity |
| FIGI | BBG0025Y4RZ3 | OpenFIGI — instrument, share class |
| CUSIP | 00287Y109 | Derived from the US/CA ISIN, check digit verified — licensed identifier, not republished as data |
6 naming systems for one entity — only codes we actually hold are listed, with no gaps filled by guessing. Sources: LEI from GLEIF (CC0), ISIN read from the issuer's own primary listing document, with its ISO 6166 check digit validated, FIGI from OpenFIGI (open standard), MIC from the ISO 10383 registry. CUSIP appears because it is arithmetically embedded in US and Canadian ISINs — we derive and verify it from a code we already hold, and we do not redistribute CUSIP Global Services data. Each linked code opens its reverse-lookup page; the validator checks any code's check digit. seed-0.7 · marketcap-1 · 2026-08-30.
Approximate reference values from public sources · seed-0.7 · marketcap-1 · 2026-08-30 · not real-time. See data & methodology.
JSONCSV No key, CORS enabled — paste any of these straight into a notebook.